Mesalazina Alfasigma

Mesalazine, the active ingredient in Mesalazina Alfasigma, is a 5‑aminosalicylic acid (5‑ASA) presented as an oral formulation for oral use. It is used to treat inflammatory bowel diseases such as ulcerative colitis and mild to moderate Crohn's disease in adult patients.

GNH USA supplies Mesalazina Alfasigma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mesalazina Alfasigma belongs to the 5‑ASA class and is indicated for inflammatory bowel disease management. - Ulcerative colitis (induction): reduces active intestinal inflammation and promotes symptom relief. - Ulcerative colitis (maintenance): helps maintain remission and prevent flare‑ups. - Crohn's disease (mild to moderate): controls colonic inflammation and supports clinical improvement.

Mesalazina Alfasigma may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Abdominal pain: cramping or discomfort in the abdomen. - Headache: transient pain in the head region. - Diarrhoea: increased loose stools.

Serious or Rare Side Effects: - Severe allergic reaction: includes rash, swelling, or anaphylaxis. - Interstitial nephritis: inflammation of kidney tissue. - Hepatic dysfunction: abnormal liver enzyme elevations. - Blood dyscrasias: such as neutropenia or agranulocytosis. - Pancreatitis: inflammation of the pancreas.

Before initiating therapy, several safety considerations are recommended. - Renal monitoring: assess kidney function periodically. - Hepatic monitoring: check liver enzymes during treatment. - Hypersensitivity assessment: watch for signs of allergic reaction. - Sulfa allergy caution: avoid if patient has known sulfonamide sensitivity. - Severe hepatic impairment: use only if benefits outweigh risks. - Store at room temperature: keep in the original pack, protect from moisture.

Mesalazina Alfasigma can interact with several medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Azathioprine: may increase myelosuppression risk. - Warfarin: can enhance anticoagulant effect, raising bleeding risk. - Oral contraceptives: may reduce hormonal efficacy.

Moderate Interactions (Monitor Closely): - NSAIDs: combined use may increase nephrotoxicity. - Lithium: mesalazine may alter lithium plasma levels. - Allopurinol: potential for increased toxicity; monitor renal function.